BioSpace News Archive

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia.

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30 company-sponsored presentations will be featured at the European Academy of Dermatology and Venereology (EADV) Congress taking place in Berlin, Germany from October 11-14, 2023.

ZKR Orthopedics, Inc., a clinical stage medical device company, today announced that its LIFT implant technology has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023.

MBX Biosciences, Inc. today announced that the first healthy adult participant has been dosed in its Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for the treatment of post-bariatric hypoglycemia (PBH).

Lexicon Pharmaceuticals, Inc. announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.

Rhaeos, Inc, a clinical stage medical device technology company, is pleased to announce that it has been awarded a $1.5 million grant from the National Institutes of Health National Institute of Neurological Disorders and Stroke through its Blueprint MedTech program.

Dyadic International, Inc. announced the appointment of Doug Pace as Executive Vice President of Business Development.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today released new data for TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting.